Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Top Cited Papers
- 9 October 2015
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 350 (6257), 207-211
- https://doi.org/10.1126/science.aad0095
Abstract
Monoclonal antibodies directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized. To investigate the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab, we analyzed whole exomes from pretreatment melanoma tumor biopsies and matching germline tissue samples from 110 patients. For 40 of these patients, we also obtained and analyzed transcriptome data from the pretreatment tumor samples. Overall mutational load, neoantigen load, and expression of cytolytic markers in the immune microenvironment were significantly associated with clinical benefit. However, no recurrent neoantigen peptide sequences predicted responder patient populations. Thus, detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors.Funding Information
- NIH (U54 HG003067)
This publication has 40 references indexed in Scilit:
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive MelanomaJournal of Clinical Oncology, 2013
- Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparationNucleic Acids Research, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012
- RNA-SeQC: RNA-seq metrics for quality control and process optimizationBioinformatics, 2012
- ContEst: estimating cross-contamination of human samples in next-generation sequencing dataBioinformatics, 2011
- A scalable, fully automated process for construction of sequence-ready human exome targeted capture librariesGenome Biology, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- GenePattern 2.0Nature Genetics, 2006